# Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

> **NCT00521092** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- AIDS-related Kaposi Sarcoma
- Classic Kaposi Sarcoma

## Interventions

- **DRUG:** sunitinib malate
- **PROCEDURE:** laboratory biomarker analysis
- **PROCEDURE:** pharmacological study

## Key facts

- **NCT ID:** NCT00521092
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-01
- **Primary completion:** 2010-10
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants enrolled.
- **Last updated:** 2014-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521092, "Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00521092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*